Published in J Neurochem on June 07, 2014
Alpha7 nicotinic receptors as therapeutic targets for Parkinson's disease. Biochem Pharmacol (2015) 0.83
Neuron matters: electric activation of neuronal tissue is dependent on the interaction between the neuron and the electric field. J Neuroeng Rehabil (2015) 0.81
Promising cannabinoid-based therapies for Parkinson's disease: motor symptoms to neuroprotection. Mol Neurodegener (2015) 0.79
Cannabinoids and Tremor Induced by Motor-related Disorders: Friend or Foe? Neurotherapeutics (2015) 0.77
The recommendations of Chinese Parkinson's disease and movement disorder society consensus on therapeutic management of Parkinson's disease. Transl Neurodegener (2016) 0.77
Marijuana Compounds: A Nonconventional Approach to Parkinson's Disease Therapy. Parkinsons Dis (2016) 0.75
Repetitive transcranial magnetic stimulation for treatment of lactacystin-induced Parkinsonian rat model. Oncotarget (2017) 0.75
Targeting adenosine A2A receptors in Parkinson's disease. Trends Neurosci (2006) 2.14
Receptor subtypes involved in the presynaptic and postsynaptic actions of dopamine on striatal interneurons. J Neurosci (2003) 1.66
ERK phosphorylation and FosB expression are associated with L-DOPA-induced dyskinesia in hemiparkinsonian mice. Biol Psychiatry (2005) 1.53
Genetic inactivation of dopamine D1 but not D2 receptors inhibits L-DOPA-induced dyskinesia and histone activation. Biol Psychiatry (2009) 1.44
Dyskinetic potential of dopamine agonists is associated with different striatonigral/striatopallidal zif-268 expression. Exp Neurol (2010) 1.44
Blockade of A2A receptors plus l-DOPA after nigrostriatal lesion results in GAD67 mRNA changes different from l-DOPA alone in the rat globus pallidus and substantia nigra reticulata. Exp Neurol (2003) 1.38
Distinct roles of D1 and D5 dopamine receptors in motor activity and striatal synaptic plasticity. J Neurosci (2003) 1.31
Striatal adenosine A2A and cannabinoid CB1 receptors form functional heteromeric complexes that mediate the motor effects of cannabinoids. Neuropsychopharmacology (2007) 1.28
Birth asphyxia as the major complication in newborns: moving towards improved individual outcomes by prediction, targeted prevention and tailored medical care. EPMA J (2011) 1.17
D1 but not D5 dopamine receptors are critical for LTP, spatial learning, and LTP-Induced arc and zif268 expression in the hippocampus. Cereb Cortex (2007) 1.15
Adenosine A2A receptor stimulation potentiates nitric oxide release by activated microglia. J Neurochem (2005) 1.10
Modafinil enhances extracellular levels of dopamine in the nucleus accumbens and increases wakefulness in rats. Behav Brain Res (2006) 1.09
The 6-hydroxydopamine model of Parkinson's disease. Neurotox Res (2007) 1.09
Expression and function of CB1 receptor in the rat striatum: localization and effects on D1 and D2 dopamine receptor-mediated motor behaviors. Neuropsychopharmacology (2007) 1.08
Microglial glucocorticoid receptors play a pivotal role in regulating dopaminergic neurodegeneration in parkinsonism. Proc Natl Acad Sci U S A (2011) 1.07
Induction of c-Fos in 'panic/defence'-related brain circuits following brief hypercarbic gas exposure. J Psychopharmacol (2010) 1.06
Associative learning and CA3-CA1 synaptic plasticity are impaired in D1R null, Drd1a-/- mice and in hippocampal siRNA silenced Drd1a mice. J Neurosci (2010) 1.06
Dynamics of the Parkinsonian striatal microcircuit: entrainment into a dominant network state. J Neurosci (2010) 1.05
Acute hypercarbic gas exposure reveals functionally distinct subpopulations of serotonergic neurons in rats. J Psychopharmacol (2005) 1.03
Dopamine D1-histamine H3 receptor heteromers provide a selective link to MAPK signaling in GABAergic neurons of the direct striatal pathway. J Biol Chem (2010) 1.02
New therapies for the treatment of Parkinson's disease: adenosine A2A receptor antagonists. Life Sci (2005) 1.02
Striatal Signaling in L-DOPA-Induced Dyskinesia: Common Mechanisms with Drug Abuse and Long Term Memory Involving D1 Dopamine Receptor Stimulation. Front Neuroanat (2011) 1.01
Anti-brain autoantibodies and altered excitatory neurotransmitters in obsessive-compulsive disorder. Neuropsychopharmacology (2009) 1.01
5-HT1A receptor agonist-mediated protection from MPTP toxicity in mouse and macaque models of Parkinson's disease. Neurobiol Dis (2006) 1.00
Molecular phenotype of rat striatal neurons expressing the dopamine D5 receptor subtype. Eur J Neurosci (2002) 1.00
Persistent MDMA-induced dopaminergic neurotoxicity in the striatum and substantia nigra of mice. J Neurochem (2008) 0.99
Inactivation of neuronal forebrain A receptors protects dopaminergic neurons in a mouse model of Parkinson's disease. J Neurochem (2009) 0.98
Persistent behavioral sensitization to chronic L-DOPA requires A2A adenosine receptors. J Neurosci (2002) 0.97
Tyrosine hydroxylase cells appearing in the mouse striatum after dopamine denervation are likely to be projection neurones regulated by L-DOPA. Eur J Neurosci (2008) 0.96
Pharmacological characterization of 50-kHz ultrasonic vocalizations in rats: comparison of the effects of different psychoactive drugs and relevance in drug-induced reward. Neuropharmacology (2012) 0.95
Inactivation of adenosine A2A receptors selectively attenuates amphetamine-induced behavioral sensitization. Neuropsychopharmacology (2003) 0.94
Anxiolytic-like effects of N,N-dialkyl-2-phenylindol-3-ylglyoxylamides by modulation of translocator protein promoting neurosteroid biosynthesis. J Med Chem (2008) 0.93
Dopamine D4 receptors are heterogeneously distributed in the striosomes/matrix compartments of the striatum. J Neurochem (2002) 0.92
Selective vulnerability in striosomes and in the nigrostriatal dopaminergic pathway after methamphetamine administration : early loss of TH in striosomes after methamphetamine. Neurotox Res (2009) 0.92
Adenosine A2A receptors in neuroadaptation to repeated dopaminergic stimulation: implications for the treatment of dyskinesias in Parkinson's disease. Neurology (2003) 0.92
Dopamine D2-receptor knockout mice are protected against dopaminergic neurotoxicity induced by methamphetamine or MDMA. Neurobiol Dis (2011) 0.92
Modification of adenosine extracellular levels and adenosine A(2A) receptor mRNA by dopamine denervation. Eur J Pharmacol (2002) 0.92
Mechanisms of nicotine actions on dorsal raphe serotoninergic neurons. Eur J Pharmacol (2002) 0.91
Late-onset Parkinsonism in NFκB/c-Rel-deficient mice. Brain (2012) 0.91
Prism adaptation in spinocerebellar ataxia type 2. Neuropsychologia (2007) 0.91
The T-box brain 1 (Tbr1) transcription factor inhibits astrocyte formation in the olfactory bulb and regulates neural stem cell fate. Mol Cell Neurosci (2010) 0.90
Effects of rTMS on Parkinson's disease: a longitudinal fMRI study. J Neurol (2011) 0.90
Long-term changes in sleep and depressive symptoms of smokers in abstinence. Nicotine Tob Res (2007) 0.90
EEG modifications in the cortex and striatum after dopaminergic priming in the 6-hydroxydopamine rat model of Parkinson's disease. Brain Res (2003) 0.88
No Lewy pathology in monkeys with over 10 years of severe MPTP Parkinsonism. Mov Disord (2009) 0.88
Are tuberomammillary histaminergic neurons involved in CO2-mediated arousal? Exp Neurol (2005) 0.87
Metabolic interactions between glutamatergic and dopaminergic neurotransmitter systems are mediated through D(1) dopamine receptors. J Neurosci Res (2007) 0.87
Perinatal asphyxia: current status and approaches towards neuroprotective strategies, with focus on sentinel proteins. Neurotox Res (2010) 0.87
Differential regulation of GAD67, enkephalin and dynorphin mRNAs by chronic-intermittent L-dopa and A2A receptor blockade plus L-dopa in dopamine-denervated rats. Synapse (2002) 0.87
Synthesis of ibuprofen heterocyclic amides and investigation of their analgesic and toxicological properties. Eur J Med Chem (2003) 0.87
Nonoccupational environmental exposure to manganese is linked to deficits in peripheral and central olfactory function. Chem Senses (2013) 0.86
Early loss of dopaminergic terminals in striosomes after MDMA administration to mice. Synapse (2008) 0.86
Adenosine A₂A receptors in striatal glutamatergic terminals and GABAergic neurons oppositely modulate psychostimulant action and DARPP-32 phosphorylation. PLoS One (2013) 0.86
Methamphetamine and Parkinson's disease. Parkinsons Dis (2013) 0.86
A new ethyladenine antagonist of adenosine A(2A) receptors: behavioral and biochemical characterization as an antiparkinsonian drug. Neuropharmacology (2009) 0.85
Role of neuroactive steroid allopregnanolone in antipsychotic-like action of olanzapine in rodents. Neuropsychopharmacology (2004) 0.85
Blockade of adenosine A2A receptors antagonizes parkinsonian tremor in the rat tacrine model by an action on specific striatal regions. Exp Neurol (2004) 0.84
Motor stimulant effects of the adenosine A(2A) receptor antagonist SCH 58261 do not develop tolerance after repeated treatments in 6-hydroxydopamine-lesioned rats. Synapse (2001) 0.84
Nrf2 deficiency potentiates methamphetamine-induced dopaminergic axonal damage and gliosis in the striatum. Glia (2011) 0.84
Rehabilitation improves dyskinesias in Parkinsonian patients: a pilot study comparing two different rehabilitative treatments. NeuroRehabilitation (2012) 0.84
Olfactory dysfunction in hereditary ataxia and basal ganglia disorders. Neuroreport (2003) 0.84
Behavioral and biochemical correlates of the dyskinetic potential of dopaminergic agonists in the 6-OHDA lesioned rat. Synapse (2008) 0.83
Adenosine A2A receptor antagonists improve deficits in initiation of movement and sensory motor integration in the unilateral 6-hydroxydopamine rat model of Parkinson's disease. Synapse (2007) 0.83
Chronic treatment with atypical neuroleptics induces striosomal FosB/DeltaFosB expression in rats. Biol Psychiatry (2004) 0.83
Narcolepsy and orexins: an example of progress in sleep research. Front Neurol (2011) 0.83
Neuronal precursors within the adult rat subventricular zone differentiate into dopaminergic neurons after substantia nigra lesion and chromaffin cell transplant. J Neurosci Res (2006) 0.83
Involvement of cannabinoid CB1 receptor in associative learning and in hippocampal CA3-CA1 synaptic plasticity. Cereb Cortex (2011) 0.82
Cannabidiol, a constituent of Cannabis sativa, modulates sleep in rats. FEBS Lett (2006) 0.82
Synthesis of new 2-arylamino-6-trifluoromethylpyridine-3-carboxylic acid derivatives and investigation of their analgesic activity. Bioorg Med Chem (2004) 0.82
Sensitization to caffeine and cross-sensitization to amphetamine: influence of individual response to caffeine. Behav Brain Res (2006) 0.82
Strain dependence of adolescent Cannabis influence on heroin reward and mesolimbic dopamine transmission in adult Lewis and Fischer 344 rats. Addict Biol (2013) 0.82
Survival rates through time of hypocretin grafted neurons within their projection site. Neurosci Lett (2006) 0.82
Assessment of symptomatic and neuroprotective efficacy of Mucuna pruriens seed extract in rodent model of Parkinson's disease. Neurotox Res (2009) 0.82
Performance of movement in hemiparkinsonian rats influences the modifications induced by dopamine agonists in striatal efferent dynorphinergic neurons. Exp Neurol (2013) 0.82
Caffeine enhances astroglia and microglia reactivity induced by 3,4-methylenedioxymethamphetamine ('ecstasy') in mouse brain. Neurotox Res (2009) 0.81
Characterization of the antiparkinsonian effects of the new adenosine A2A receptor antagonist ST1535: acute and subchronic studies in rats. Eur J Pharmacol (2007) 0.81
Administration of URB597, oleoylethanolamide or palmitoylethanolamide increases waking and dopamine in rats. PLoS One (2011) 0.81
Is nicotine protective against Parkinson's disease? An experimental analysis. CNS Neurol Disord Drug Targets (2012) 0.81
L-DOPA-induced increase in TH-immunoreactive striatal neurons in parkinsonian mice: insights into regulation and function. Neurobiol Dis (2012) 0.81
The nonpsychoactive Cannabis constituent cannabidiol is a wake-inducing agent. Behav Neurosci (2008) 0.81
Adenosine A2A receptor antagonism increases striatal glutamate outflow in dopamine-denervated rats. Eur J Pharmacol (2003) 0.81
Antidepressant-like effects of nicotine and transcranial magnetic stimulation in the olfactory bulbectomy rat model of depression. Brain Res Bull (2008) 0.81
Biomarkers for prediction and targeted prevention of Alzheimer's and Parkinson's diseases: evaluation of drug clinical efficacy. EPMA J (2010) 0.81
Nicotinamide prevents the long-term effects of perinatal asphyxia on apoptosis, non-spatial working memory and anxiety in rats. Exp Brain Res (2009) 0.81
Impulse control disorders and dopamine dysregulation syndrome associated with dopamine agonist therapy in Parkinson's disease. Behav Pharmacol (2009) 0.81
Potentiation of amphetamine-mediated responses in caffeine-sensitized rats involves modifications in A2A receptors and zif-268 mRNAs in striatal neurons. J Neurochem (2006) 0.80
Molecular dissection of dopamine receptor signaling. J Chem Neuroanat (2002) 0.80
Adenosine A2A and dopamine receptor interactions in basal ganglia of dopamine denervated rats. Neurology (2003) 0.80
How reliable is the behavioural evaluation of dyskinesia in animal models of Parkinson's disease? Behav Pharmacol (2006) 0.80
A critical evaluation of behavioral rodent models of motor impairment used for screening of antiparkinsonian activity: The case of adenosine A(2A) receptor antagonists. Neurotox Res (2013) 0.80